281 related articles for article (PubMed ID: 24035431)
1. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
[TBL] [Abstract][Full Text] [Related]
2. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
5. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S; Michielin O; Zimmermann S
J Clin Oncol; 2013 Jul; 31(20):e341-4. PubMed ID: 23733758
[No Abstract] [Full Text] [Related]
6. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
7. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
8. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
[No Abstract] [Full Text] [Related]
11. Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.
Jenkinson HA; Siroy AE; Choksi A
J Drugs Dermatol; 2017 Oct; 16(10):1050-1052. PubMed ID: 29036262
[TBL] [Abstract][Full Text] [Related]
12. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
15. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
[TBL] [Abstract][Full Text] [Related]
18. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
19. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
20. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
